Literature DB >> 11589918

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.

E Vanmechelen1, H Vanderstichele, F Hulstaert, N Andreasen, L Minthon, B Winblad, P Davidsson, K Blennow.   

Abstract

The reliability of cerebrospinal fluid (CSF)-tau and CSF-beta-amyloid assays for diagnosis of Alzheimer's disease and other dementing disorders such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and Creutzfeldt-Jakob disease (CJD) is reviewed. CSF assessment of the two proteins is useful in early diagnosis of AD and to differentiate it from FTD and DLB. Extremely high CSF-tau levels can discriminate CJD from AD.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11589918     DOI： 10.1016/s0047-6374(01)00304-9

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN： 0047-6374            Impact factor:   5.432


  7 in total

1.  Tau haplotype affects CSF Tau levels in frontotemporal dementia: implication for diagnostic purposes.

Authors:  B Borroni; M Di Luca; A Padovani
Journal:  J Neurol       Date:  2006-05-24       Impact factor: 4.849

2.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease.

Authors:  B Van Everbroeck; S Quoilin; J Boons; J J Martin; P Cras
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

3.  [Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia].

Authors:  J Hort; M Valis; G Waberzinek; R Taláb; L Glossová; M Bojar; M Vyhnálek; D Skoda; J Masopust; P Stourac
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

4.  A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect.

Authors:  Erfan Younesi; Martin Hofmann-Apitius
Journal:  J Transl Med       Date:  2013-07-26       Impact factor: 5.531

5.  CSF tau and β-amyloid as biomarkers for mild cognitive impairment.

Authors:  Harald Hampel; Kaj Blennow
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

6.  Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.

Authors:  Shieh-Yueh Yang; Ming-Jang Chiu; Ta-Fu Chen; Chin-Hsien Lin; Jiann-Shing Jeng; Sung-Chun Tang; Yen-Fu Lee; Che-Chuan Yang; Bing-Hsien Liu; Hsin-Hsien Chen; Chau-Chung Wu
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

7.  Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature.

Authors:  Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.